Tocilizumab Leads to Improvement in Patients With Active Polymyalgia Rheumatica Despite Prednisone Therapy

September 25th 2022, 1:32pm


However, patient-reported scores were not significantly better in the tocilizumab group.

Secukinumab Effective in Real-world Clinical Usage in New Study

September 20th 2022, 12:34pm


At 12 weeks, nearly 8 in 10 patients had significant improvement.

Researchers Identify Key Protein Driving Inflammation in RA

September 18th 2022, 3:30pm


The findings, produced over a 4-year period, indicate the protein sulfatase-2 (Sulf-2) may be a therapeutic target in rheumatoid arthritis (RA).

Improved CPMs Needed for Guiding Methotrexate Use in RA

September 16th 2022, 3:36pm


The study analyzed 20 clinical prediction models (CPMs) for rheumatoid arthritis (RA), all of which were deemed to have a high risk of bias, leading the researchers to urge against their use to guide decision-making without addressing their limitations.

Systemic Review, Survey of Physicians Provide Insight on Targeted Therapy Use in SSc-ILD

September 13th 2022, 1:18pm


Data from a literature review of 41 studies were analyzed and subsequently leveraged to create a survey among physicians on the use of 4 targeted therapies in systemic sclerosis-interstitial lung disease (SSc-ILD).

Low-Dose Secukinumab Shows Best PASI 90 in Pediatric Plaque Psoriasis

September 7th 2022, 5:15pm


This analysis of 5 studies found that, compared with placebo, all biologic regimens improved Psoriasis Area and Severity Index (PASI) 90 response—considered a gold standard goal due to its correlation with quality of life.

RA2-DREAM Challenge Demonstrates Successful Crowdsourcing Approach in Developing Joint Damage Algorithms

September 2nd 2022, 10:04pm


Machine learning models collected using a crowdsourcing approach that provide feasible, quick, and accurate methods to quantify joint damage in rheumatoid arthritis (RA) could potentially be incorporated into electronic health records.

Alternative Therapies Possible for Refractory Systematic Onset JIA, Review Says

August 29th 2022, 7:55pm


About 1 in 7 people with systematic onset juvenile idiopathic arthritis (SJIA) will not respond to interleukin-1 or interleukin-6 inhibitors.

Periodontal Treatment May Improve Short-term RA Disease Activity

August 26th 2022, 4:09pm


Investigators conducted a review of 21 studies on the effects of a gum disease treatment on various rheumatoid arthritis (RA) disease activity measures.

Secukinumab Linked to Longer Time to JIA Disease Flare

August 23rd 2022, 4:49pm


Juvenile idiopathic arthritis (JIA) disease flare was significantly longer in children with enthesitis-related arthritis and juvenile psoriatic arthritis treated with secukinumab compared with placebo.